v3.26.1
Revenue and government financing for research expenditures - Disclosure of Changes in Deferred Revenue and Collaboration Liabilities (Details)
€ in Thousands, $ in Millions
 12 Months Ended
Jun. 30, 2022
USD ($)
Jun. 30, 2022
EUR (€)
Dec. 31, 2025
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Deferred tax liabilities / Deferred revenue          
Deferred Revenue, Roll Forward [Abstract]          
Contract liabilities at beginning of period     € 3,441 € 10,483 € 14,481
Revenue for the current financial year     (620) (6,504) (12,373)
Transfer from collaboration liabilities     (5) 536 (173)
Contract liabilities at end of period     2,826 3,441 10,483
Total          
Contract liabilities at beginning of period     3,441 10,483 14,481
Contract liabilities at end of period     2,826 3,441 10,483
Deferred tax liabilities / Deferred revenue | 2015 monalizumab agreement, with AstraZeneca          
Deferred Revenue, Roll Forward [Abstract]          
Contract liabilities at beginning of period     215 5,156 14,481
Revenue for the current financial year     (220) (4,404) (9,499)
Transfer from collaboration liabilities     5 (536) 173
Contract liabilities at end of period     0 215 5,156
Total          
Contract liabilities at beginning of period     215 5,156 14,481
Contract liabilities at end of period     0 215 5,156
Collaboration liabilities | 2015 monalizumab agreement, with AstraZeneca          
Deferred Revenue, Roll Forward [Abstract]          
Contract liabilities at beginning of period     48,571 52,677 63,211
Contract liabilities at end of period     38,249 48,571 52,677
Current          
Current contract liabilities at beginning of period     7,443 7,647 10,223
Additions     9,521 4,303 7,785
Repayment cost to AZ     (4,792) (7,772) (8,423)
Fx impact     (5,671) 3,265 (1,938)
Current contract liabilities at end of period     6,501 7,443 7,647
Non-Current          
Non-current contract liabilities at beginning of period     41,128 45,030 52,988
Additions     (9,380) (3,902) (7,958)
Repayment cost to AZ     0 0 0
Fx impact     0 0 0
Non-current contract liabilities at end of period     31,748 41,128 45,030
Total          
Contract liabilities at beginning of period     48,571 52,677 63,211
Additions $ 36.0 € 34,300 141 401 (173)
Repayment cost to AZ     (4,792) (7,772) (8,423)
Fx impact     (5,671) 3,265 (1,938)
Contract liabilities at end of period     38,249 48,571 52,677
Collaboration liabilities | Agreement with Takeda on research of Antibody Drug Conjugates (ADC)          
Deferred Revenue, Roll Forward [Abstract]          
Contract liabilities at beginning of period     3,226 5,327 0
Contract liabilities at end of period     2,826 3,226 5,327
Total          
Contract liabilities at beginning of period     3,226 5,327 0
Additions     0 0 8,200
Repayment cost to AZ     (400) (2,101) (2,874)
Contract liabilities at end of period     € 2,826 € 3,226 € 5,327